Citi analyst Joel Beatty downgraded Esperion Therapeutics (NASDAQ: ESPR) from Buy to Neutral with a price target of $82.00 (from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE